Payden & Rygel Investment Group Gilead Sciences, Inc. Transaction History
Payden & Rygel Investment Group
- $1.24 Billion
- Q2 2024
A detailed history of Payden & Rygel Investment Group transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Payden & Rygel Investment Group holds 180 shares of GILD stock, worth $16,443. This represents 0.0% of its overall portfolio holdings.
Number of Shares
180
Previous 2,680
93.28%
Holding current value
$16,443
Previous $196,000
93.88%
% of portfolio
0.0%
Previous 0.01%
Shares
4 transactions
Others Institutions Holding GILD
# of Institutions
1,927Shares Held
994MCall Options Held
10.5MPut Options Held
9.75M-
Black Rock Inc. New York, NY121MShares$11 Billion0.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA115MShares$10.5 Billion0.18% of portfolio
-
Capital World Investors Los Angeles, CA76.5MShares$6.99 Billion1.03% of portfolio
-
Capital Research Global Investors Los Angeles, CA61.8MShares$5.65 Billion1.12% of portfolio
-
State Street Corp Boston, MA60.2MShares$5.5 Billion0.21% of portfolio
About GILEAD SCIENCES, INC.
- Ticker GILD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 1,253,369,984
- Market Cap $114B
- Description
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...